Trial Outcomes & Findings for Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence (NCT NCT00223236)

NCT ID: NCT00223236

Last Updated: 2014-08-11

Results Overview

Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

44 participants

Primary outcome timeframe

Biweekly (visit) urine drug screens

Results posted on

2014-08-11

Participant Flow

Patients were recruited from local community behavioral healthcare clinics and through advertising in local publications. The recruitment period was from 5/1/2004 to 4/12/2005.

Participants were randomized to medication assignment after meeting the inclusion and exclusion criteria and completing the Institutional Review Board(IRB)-approved informed consent process.

Participant milestones

Participant milestones
Measure
Citicoline
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
Inactive ingredient matching the active medication in appearance
Overall Study
STARTED
16
18
Overall Study
COMPLETED
9
4
Overall Study
NOT COMPLETED
7
14

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Citicoline
n=23 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=21 Participants
Inactive ingredient matching the active medication in appearance
Total
n=44 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
n=99 Participants
21 Participants
n=107 Participants
44 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Continuous
42.1 years
STANDARD_DEVIATION 6.6 • n=99 Participants
40.7 years
STANDARD_DEVIATION 8.0 • n=107 Participants
41.4 years
STANDARD_DEVIATION 7.1 • n=206 Participants
Sex: Female, Male
Female
10 Participants
n=99 Participants
11 Participants
n=107 Participants
21 Participants
n=206 Participants
Sex: Female, Male
Male
13 Participants
n=99 Participants
10 Participants
n=107 Participants
23 Participants
n=206 Participants
Region of Enrollment
United States
23 participants
n=99 Participants
21 participants
n=107 Participants
44 participants
n=206 Participants
Inventory of Depressive Symptomatology
43.6 Units on a scale
STANDARD_DEVIATION 10.6 • n=99 Participants
38.7 Units on a scale
STANDARD_DEVIATION 13 • n=107 Participants
41.26 Units on a scale
STANDARD_DEVIATION 11.9 • n=206 Participants
Young Mania Rating Scale
11.2 Units on a scale
STANDARD_DEVIATION 4.9 • n=99 Participants
11.5 Units on a scale
STANDARD_DEVIATION 7.0 • n=107 Participants
11.34 Units on a scale
STANDARD_DEVIATION 5.89 • n=206 Participants
Rey Auditory Verbal Learning Scale
36.6 T scores
STANDARD_DEVIATION 10.0 • n=99 Participants
36.0 T scores
STANDARD_DEVIATION 9.0 • n=107 Participants
36.33 T scores
STANDARD_DEVIATION 9.47 • n=206 Participants
cocaine used
No cocaine used
19 participants
n=99 Participants
19 participants
n=107 Participants
38 participants
n=206 Participants
cocaine used
Cocaine used
4 participants
n=99 Participants
1 participants
n=107 Participants
5 participants
n=206 Participants
cocaine used
Unknown
0 participants
n=99 Participants
1 participants
n=107 Participants
1 participants
n=206 Participants

PRIMARY outcome

Timeframe: Biweekly (visit) urine drug screens

Population: Number of participants are those who completed baseline assessment and at least one treatment visit followed by baseline.

Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks.

Outcome measures

Outcome measures
Measure
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
Cocaine Use Determined by Urine Analysis
62.50 percentage of participants no cocaine
50.00 percentage of participants no cocaine

SECONDARY outcome

Timeframe: Change in scores between baseline and exit (exit - baseline).

Population: Number of participants reported are those who completed baseline assessment and at least one treatment visit.

The IDS-SR is a 30 item self report used to assess the severity of depressive symptoms. The each item has a 4-likert scale, 0 to 3, with 3 representing the worst symptom. The total score of IDS-SR is calculated as a sum of each item score. The range of possible score is between 0 and 90, 0 as no symptom and 90 the worst symptom. The higher the score, the more severe the depression. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the tudy period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline).

Outcome measures

Outcome measures
Measure
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
Inventory of Depressive Symptomatology Self Report (IDS-SR).
-20.54 units on scale
Standard Deviation 14.56
-11.89 units on scale
Standard Deviation 14.45

SECONDARY outcome

Timeframe: Baseline to exit (exit score - baseline score)

Population: Numbers of participants are those who completed baseline assessment and at least one treatment visit.

The YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal and and 4 or 8 =most abnormal. The total possible score is 0 to 60, 0 being no symptom and 60 the worst symptom. The higher the score, the worse the mania symptoms are. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline).

Outcome measures

Outcome measures
Measure
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
Young Mania Rating Scale(YMRS).
-2.00 units on a scale
Standard Deviation 8.03
-2.88 units on a scale
Standard Deviation 5.68

SECONDARY outcome

Timeframe: Change in T scores between baseline and exit (exitT score - baseline T score).

Population: number of participants are calculated based on those who completed baseline and at least one treatment visit.

The RAVLT consists of 15 nouns read aloud for five consecutive trials with each trial followed by a free-recall trial. The total score is the total number of words recalled through the five trials. Normative RAVLT T-scores was used. the higher T score, the better memory. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in RAVLT T scores between baseline and exit (exit - baseline).

Outcome measures

Outcome measures
Measure
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=17 Participants
Inactive ingredient matching the active medication in appearance
Rey Auditory Verbal Learning Test(RAVLT)
7.06 T score
Standard Deviation 11.79
3.14 T score
Standard Deviation 7.07

Adverse Events

Citicoline

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo

Serious events: 2 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Citicoline
n=23 participants at risk
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
Placebo
n=21 participants at risk
Inactive ingredient matching the active medication in appearance
Skin and subcutaneous tissue disorders
Skin rash
4.3%
1/23 • Number of events 1
4.8%
1/21 • Number of events 1
Psychiatric disorders
Hypomania
0.00%
0/23
4.8%
1/21 • Number of events 1

Other adverse events

Adverse event data not reported

Additional Information

E. Sherwood Brown, M.D., Ph.D., Professor

The University of Texas Southwestern Medical Center

Phone: 214-645-6950

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place